| Status: Assessment pending - company submission requested | |
Treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. The AWMSG Scrutiny Panel considered bimekizumab suitable for a full assessment at their meeting on 07/08/2025. |
|
Medicine details |
|
| Medicine name | bimekizumab (Bimzelx®) |
| Formulation | subcutaneous injection |
| Reference number | 4510 |
| Indication | As above |
| Company | UCB Pharma Ltd |
| BNF chapter | Skin |
| Assessment type | Full |
| Status | Assessment pending - company submission requested |
| Scrutiny Panel meeting date | 07/08/2025 |
| LOWMAG meeting date | TBC |
| AWMSG meeting date | TBC |
| NICE guidance | TA1028: Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) |
| Further information The AWMSG Scrutiny Panel considered bimekizumab suitable for a full assessment at their meeting on 07/08/2025. Bimekizumab (Bimzelx®) is suitable for a full HTA assessment via the Licensed Medicines One Wales Medicines Assessment Group (LOWMAG). Unmet clinical need has been identified. There are no UK clinical guidelines currently recommending this treatment and this medicine has not been appraised by NICE (NICE terminated). |
|